Navigation Links
Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients
Date:12/30/2008

WASHINGTON, Dec. 30 /PRNewswire-USNewswire/ -- The Coalition for 21st Century Medicine strongly opposes the citizen petition filed by Genentech, Inc. on December 5, 2008, seeking to restrict the ability of laboratories to offer diagnostic tests to physicians and patients. The request threatens innovation in laboratory tests, would harm patient care and rests on flawed scientific and legal premises.

The Coalition's mission is to encourage the research, development, and commercialization of innovative diagnostic techniques. In contrast, the petition, by requesting that the FDA approve all laboratory tests, would delay the introduction of many critically needed diagnostic tests, and prevent others from ever being available. Further, although implied to be narrow, the petition is sweeping in scope. Genentech maintains that the Food and Drug Administration (FDA) should regulate all laboratory developed tests (LDTs) "for use in drug or biologic therapeutic decision making." LDTs are developed precisely for the purpose of helping physicians make therapeutic decisions for their patients, including the decision of which drug to prescribe. The overwhelming majority of LDTs fall within the scope of the petition.

Genentech's citizen petition relies on several incorrect assumptions. One of the most fundamental errors is that FDA review and approval is needed for all LDTs used in therapeutic decision-making "to ensure that claims made for the tests are scientifically proven." Genentech wrongly asserts that FDA approval is a prerequisite for claims to be considered "scientifically proven." FDA approval is not needed for a LDT's performance to be demonstrated. There are many other methods of establishing a LDT's performance, such as the publication of reproducible research findings in peer-reviewed publications. Doctors routinely use peer-reviewed published literature in making therapeutic decisions, including the decision to prescribe drugs for off-label uses that have not been approved by FDA.

In seeking to require FDA approval of all LDTs used to make therapeutic decisions, Genentech relies on statements which it alleges are "unsubstantiated" relating to LDTs affecting usage of its own products. There is a vast difference between not knowing how much data support a particular claim, and whether the claim is actually unsubstantiated. A lack of information about some LDTs does not justify a revolutionary change in the regulatory regime for laboratories. Moreover, imposing FDA regulation is not needed to redress false or misleading claims. The Federal Trade Commission has jurisdiction over that type of misconduct, as do the existing state agencies that regulate laboratories. Concerns about allegedly inaccurate statements can be readily -- and efficiently -- addressed within the existing regulatory framework.

The petition entirely ignores that a rigorous, well-established regulatory system already exists for LDTs. Laboratories and their tests need to meet the demanding requirements under the Clinical Laboratory Improvement Amendments (CLIA). They are also regulated by various states, as well as professional societies. Superimposing FDA approval of LDTs on top of the existing regulatory requirements would result in redundant -- and even conflicting -- regulation.

The Coalition for 21st Century Medicine, as well as many other organizations, questions whether FDA has the authority to regulate LDTs. However, as Genentech acknowledges, even if the FDA were to seek to regulate LDTs, the agency needs to proceed through notice-and-comment rulemaking. Until that process is completed, FDA cannot take enforcement action against laboratories for offering LDTs. Singling out individual laboratories for ad hoc enforcement, based on unstated criteria, can only result in arbitrary and capricious decisions. Asserting that FDA rulemaking is "a complex, lengthy process," Genentech requests that FDA punish companies before developing its regulations. The rights of laboratories to due process and fundamental fairness cannot be subordinated to a desire for haste.

Overturning the existing regulatory regime for LDTs would impose huge costs on laboratories. Even when a company possesses the data necessary to obtain FDA approval, companies still incur huge regulatory costs -- and delays -- in navigating the FDA approval process. Laboratories would incur significant additional costs to develop and implement systems that meet FDA's Good Manufacturing Practice regulations. Requiring FDA approval or clearance of every LDT used to make drug-related therapeutic decisions would cost the health care system a staggering amount of money. Nevertheless, Genentech's single paragraph on Economic Impact essentially ignores all of these direct economic costs, as well as all the health care costs that the health care system will bear because new LDTs will not be available. Genentech also entirely overlooks the costs to FDA of reviewing these submissions, and the impact on FDA's ability to handle its existing workload of diagnostic products.

The Coalition for 21st Century Medicine is committed to the development and dissemination of novel, scientifically robust and clinically useful diagnostic tests. Genentech's citizen petition requests the FDA to take actions that would preclude those objectives from being realized. We will be submitting to the docket a more detailed analysis explaining why the citizen petition should be rejected.

The Coalition for 21st Century Medicine represents some of the world's most innovative diagnostic technology companies, clinical laboratories, researchers, physicians, venture capitalists, and patient advocacy groups -- all linked by a common mission to develop advanced diagnostics that improve the quality of healthcare for patients.


'/>"/>
SOURCE The Coalition for 21st Century Medicine
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result
2. AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward
3. Childhood Influenza Immunization Coalition Encourages Vaccination Throughout the Influenza Season
4. Cancer Cure Coalition Proposes Major Changes at the FDA
5. St. Jude Settles Century-Old Debate on Origin of Mammalian Network of Lymphatic Vessels
6. Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers
7. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
8. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
9. Personalized Medicine - The Genomic Revolution in Cardiac Care
10. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
11. U.S. Preventive Medicine Acquires Specialty Disease Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017 Caris Life ... on fulfilling the promise of precision medicine, today ... the benefits of its molecular profiling approach in ... comprehensive genomic profiling plus (CGP+) with Caris Molecular ... tumor on a molecular level, leading to more ...
(Date:9/7/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ), ... cell and tissue hypothermic storage and cryopreservation ... President and CEO, will be presenting at two investment conferences ... 19 th Annual Global Investment Conference on Tuesday, September ... The conference is being held at the New York Palace ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... Illustrate, Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time ... Rights (OCR) HIPAA audit and properly satisfy the law. , Thanks to the ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... and social campaign, “Humans With Vaginas.” The goal is to ignite conversation via ... non-toxic personal care products. The brand has declared September “Humans with Vaginas” month, ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Trials I Face to Receive ... he emotionally pens his aspirations and goals to better one’s life through God. “The ... Green, while searching in all the wrong places, found a love for writing. Green ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment ... 8, and Monday, September 11, off work and rolled up their sleeves to help ... to local homes to start the process of rebuilding. , CORDA founder Bonner C. ...
Breaking Medicine News(10 mins):